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Background: Although most animal stroke studies have demonstrated potent neuroprotective effects of estrogens,
there are a number of articles reporting the opposite. In 2009, we made the case that this dichotomy was related
to administered estrogen dose. Several other suggestions for the discordant results have also been propagated,
including the age of the experimental animals and the length of hypoestrogenicity prior to estrogen administration.
These two suggestions have gained much popularity, probably because of their kinship with the window of
opportunity hypothesis, which is commonly used to explain the analogous dichotomy among human studies.
We were therefore encouraged to perform an updated meta-analysis, and to improve it by including all relevant
variables in a large multiple regression model, where the impact of confounders could be controlled for.
Results: The multiple regression model revealed an indisputable impact of estrogen administration mode on the
effects of estrogens in ischemic stroke. Subcutaneous slow-release pellets differed from the injection and silastic capsule
treatments in terms of impact of estrogens on ischemic stroke, showing that the first mentioned were more prone to
render estrogens damaging. Neither the use of elderly animals nor the adoption of longer wash-out periods influenced
estrogens’ effects on experimental ischemic stroke in rats.
Conclusions: We conclude that the discordant results regarding estrogens’ effects in rat models of ischemic stroke are
a consequence of differences in estrogen administration modes. These results are not only of importance for the
ongoing debate regarding menopausal hormone therapy, but also have an important bearing on experimental stroke
methodology and the apparent translational roadblock for suggested stroke interventions.
Keywords: Cerebral ischemia, Estradiol, Estrogens, Meta-analysis, Rats, StrokeBackground
Estrogens’ effects in focal cerebral ischemia have been a
matter of debate for more than a decade. Among studies
performed in humans, the early epidemiological studies, in-
dicating decreased stroke incidence from peri-menopausal
hormone therapy [1-3], starkly contrasted later randomized
controlled trials, such as the Women’s Health Initiative
[4]. In an effort to explain the discrepant results, the
window of opportunity hypothesis has been propagated,
stating that estrogen therapy may be detrimental after a* Correspondence: jakob.strom@oru.se
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article, unless otherwise stated.longer period of hypoestrogenicity [5]. To complement
the human studies, a large number of animal studies
have been devoted to investigate the impact of estrogens
on artificially induced ischemic stroke. Even if the vast
majority of animal studies have reported protection
from estrogens [6,7], there are some studies where the
hormone has been observed to increase infarction [8,9],
thus paralleling the dichotomy among human studies.
The most popular suggestions to explain the discordant
results in animal studies has, in analogy with the human
studies, been that differences in length of wash-out time
between ovariectomy and estrogen administration or
animal age are the responsible factors [10,11].
In 2009, a systematic analysis from our lab suggested that
the use of different estrogen administration modes may ex-
plain the dichotomous results from the animal studies [12].entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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cause it is not readily extrapolated to the human studies,
where the range of tested dosages and administration
modes is extremely narrow, the fact that all animal studies
that reported damage from estrogen used the same type of
estrogen administration seemed an unlikely coincidence. In
the studies included in the former systematic analysis, the
only administration mode capable of rendering estro-
gens damaging was a type of subcutaneous slow-release
pellet (produced by the company Innovative Research of
America®), which has been demonstrated to produce ex-
tremely high, prolonged serum 17β-estradiol concentra-
tions in rodents [13-15]. However, in the 2009 systematic
analysis, separate analyses handled one variable at a time,
and thus confounders were not controlled for. The discus-
sion regarding what factors contribute to the estrogen-
stroke dichotomy has nevertheless proceeded, and for ex-
ample in a recent review, Sohrabji et al. suggested that the
factors age, hypertension, rat strain and whether the middle
cerebral artery occlusion (MCAo) was permanent or not
could explain why some articles report enlarged infarcts
from estrogen administration. The fact that slow-release
pellets had been used in all cited studies in which estrogens
had increased damage was not even mentioned [16].
The statistical shortcomings of the previous systematic
analysis, the continuing debate on the matter and the
publication of several additional original studies since
the previous systematic analysis encouraged us to per-
form an updated and improved meta-analysis, where all
methodological differences that reasonably could affect
the impact of estrogens on experimental ischemic stroke
would be controlled for in a large multiple regression
model. The current meta-analysis therefore aimed to ad-
dress the hypotheses that (A) estrogen administration
mode, (B) the age of the experimental animals and (C)
the length of hypoestrogenicity affects estrogens’ impact
on stroke.
Results
Slow release pellets render estrogens significantly less
protective/more damaging
Sixty-one studies, describing 124 pairs of estrogen-treated
groups and control groups (subsequently referred to as
“group pairs”) of rats in which focal cerebral ischemia was
induced, were included (Figure 1), and data regarding
methodology and results was extracted for meta-analysis
(Table 1). In the final multiple regression model, with cor-
rection for all included confounding factors, the effects of
estrogens on focal cerebral ischemia was clearly affected
by the mode of estrogen administration. Slow-release pel-
lets rendered estrogens significantly more damaging/less
protective than if the estrogens were administered via in-
jections or silastic capsules (p < 0.001; Figure 2, Table 2).
The use of direct, mechanical MCAo procedures, laser-Doppler flowmetry surveillance, edema correction and the
variable Length of time between initiation of estrogen ad-
ministration and induction of the ischemic damage were
also found to significantly influence the impact of estro-
gens on focal cerebral ischemia. Notably, concerning the
abovementioned hypotheses B and C, the factors Elderly
rats and Washout were excluded in the preceding Back-
ward analysis due to too low impact on the outcome va-
riable Infarct size ratio between estrogen treated and control
rats (subsequently referred to as “EC-ratio”; Table 2).
The final multiple regression model included 124 group
pairs, and yielded an r2-value of 0.484, hence explaining
48.4% of the variation in EC-ratio.
Higher dose in slow-release pellets increases the risk of
estrogen exacerbating ischemic damage
Simple linear regression analyses including only group pairs
within one specific estrogen administration mode category
were run with dose (μg/pellet, daily injected dosage in μg
and μg/silastic capsules, respectively) as the independent
factor and EC-ratio as the outcome variable. There was a
significant, positive relation between slow-release pellet
dose and EC-ratio (y = 72.8 + 0.05x; p = 0.001; N = 39),
meaning that increasing the pellet dose increased the
likeliness that estrogens would be damaging. This model
had an r2-value of 0.26, indicating that it explained 26%
of the EC-ratio variation (Figure 3). Adding the factor
Elderly rats (to address hypothesis B) to the model did
not affect the r2-value (0.26), and there was not even a
slight tendency for increased damage in elderly rats (re-
gression coefficient −2.9, with confidence intervals −56.1
to 50.2). A similar analysis to address hypothesis C could
not be done since only one single study administered es-
trogen via pellets more than 14 days after ovariectomy.
For the group pairs administered estrogens via injec-
tion or silastic capsules, there were no significant rela-
tions between dosage and EC-ratio, however the trend
in both models was that increased estrogen dose in-
creased neuroprotection (Injection dose vs. EC-ratio: y =
62.8-0.002x; p = 0.14; N = 50; Silastic capsule dose vs.
EC-ratio: 63.2-0.05x; p = 0.17; N = 31).
Descriptive statistics
The frequencies of categories in the 124 included group
pairs are depicted in Figure 4. Two variables, Diseases
and Estrogen type, were excluded from the statistical
analyses because too few group pairs deviated from the
dominant category. Descriptive statistics for the continu-
ous variables are presented in Table 3.
Discussion
The main multiple regression model, controlling for all
listed confounders, revealed an indisputable impact of
estrogen administration mode on the effects of estrogens
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Figure 1 Three hundred and thirty-three articles were assessed
for inclusion according to criteria A to I. Consensus was reached
to finally include 61 articles, of which 45 were included in the
previous systematic analysis, and 16 were not [12].
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nificantly differed from the injection and silastic capsule
treatments in terms of resulting EC-ratio, showing that
slow-release pellets are more prone to render estrogens
damaging. Of note, the slow-release pellet confidence
interval extended over the 100% EC-ratio line, underscor-
ing the potential for harm as well as benefit (Figure 2,
Table 2). In an attempt to further shed light on this finding,
administration mode-specific simple regression models be-
tween dose and EC-ratio were run. While no statistically
significant relation was seen between dose and EC-ratio in
the injection and silastic capsule group pairs, higher slow-
release pellet dose was clearly related to increased ischemic
damage (Figure 3).
A plausible explanation for the tendency of estrogens
in slow-release pellets to be less protective/more dam-
aging is that this high-dose administration mode causes
extremely high, elevated serum 17β-estradiol concentra-
tions. It has repeatedly been shown that the pellets from
Innovative Research of America®, albeit with a large por-
tion of unpredictability, render prolonged serum concen-
trations that are well beyond the physiological spectrum.
Silastic capsules produce serum concentrations in a
much lower, often physiological, range, while daily injec-
tions result in hours-long spikes followed by estrogen-
deficient intervals, rendering the 24 h-average serum
concentrations low [13-15]. The finding that higher pel-
let dose increased the detrimental tendency (Figure 3) is
well in line with the hypothesis that the administered
dose is the culprit. Such an explanation is reflected in
the concept of hormesis, stating that dose–response
curves are not always unidirectional, but that a sub-
stance can have diametrically different effects in differ-
ent concentration ranges [17,18]. The current meta-
analysis strongly suggests that low-dose estrogen therapy
is protective in rat models of focal cerebral ischemia,
while high-dose estrogen therapy is more likely to be
detrimental. Recently, a study aiming to experimentally
test this hypothesis was published in BMC Neurosci-
ence. The main finding was that true hormesis, with bi-
directional effects in different dose ranges compared to
baseline, could be demonstrated in the in vitro oxygen-
glucose deprivation experiments. When different doses
of 17β-estradiol in analogy were tested on rats, higher
doses rendered less protection than low doses [19].
While there is a multitude of narrative reviews covering
the field of animal models of stroke and estrogens, to
the best of our knowledge only one systematic review,
except for the 2009 article from our lab referred to in
Table 1 Extracted variables
Factor/outcome measure Data type Final categories/unit Reference category for regression analyses
Rat properties
Strain Category I. Sprague Dawley Sprague Dawley
II. Wistar
III. Other strains
Sex Category I. Female Female
II. Male
Diseases Category I. Healthy Healthy
II. Diabetes
III. Hypertension
Elderly rats Category [No] [No]
[Yes]
Number of rats in estrogen treated and control groups Continuous NA
Estrogen administration
Estrogen administration mode Category I. Slow-release pellets Slow-release pellets
II. Injections
III. Silastic capsules




Slow-release pellets: estrogen dose/pellet Continuous μg NA
Injections: Daily estrogen dose Continuous μg/kg body weight NA
Silastic capsules: estrogen dose/silastic capsule Continuous μg NA
Washout (Length of time between ovariectomy and estrogen administration) Category I. 0–14 days 0-14 days
II. >14 days



























Table 1 Extracted variables (Continued)
Occlusion duration Category I. Permanent Permanent
II. Short transient (up to 60 minutes)
III. Long transient (>60 min)
Laser-Doppler flowmetry during surgery Category [No] [No]
[Yes]
Analysis procedure
Length of time between ischemia and evaluation of damage Edema correction Continuous Hours NA
Edema correction Category I. No edema correction used No edema correction used
II. Correcting for edema in infarct
III. Correcting for edema in entire hemisphere
Outcome measures
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Figure 2 After controlling for confounding factors, it remained
clear that slow-release pellets rendered significantly higher
EC-ratios than the injection and silastic capsule regimens did
(p < 0.001). The black diamonds mark the mean EC-ratio with 95%
confidence interval for each of the three administration modes. Of
note, the slow-release pellet diamond reaches over the 100%
EC-ratio line, demonstrating the pellets’ potential for harm as well as
protection. EC-ratio = infarct size in estrogen treated group divided
by infarct size in control group.
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presented in that article was that estrogens seemed to re-
duce ischemic damage in a positive dose-dependent man-
ner [20], a result that could not be corroborated by the
current review. The previous review differed fundamentally
from the current meta-analysis by not analyzing differences
between studies reporting neuroprotection versus studies
reporting increased damage from estrogens.
Regarding hypothesis B, no impact of the use of elderly
animals on estrogens’ effects in stroke was seen. In the
preceding Backward multiple regression analysis, the vari-
able was the first one to be excluded, without even a trace
of higher EC-ratio in elderly rats (regression coefficient
before exclusion: -2.6, 95% confidence intervals −29.2 to
24.0; p = 0.85). If anything, the regression coefficient sug-
gested more estrogenic protection in elderly animals, in
contrary to hypothesis B.
Similarly for hypothesis C, the second (dummy) vari-
able to be excluded in the Backward analysis was the
wash-out category >14 days (regression coefficient be-
fore exclusion: -6.6, 95% confidence intervals −44.1 to
30.9; p = 0.73). In analogy with the use of elderly rats, the
regression coefficient pointed in the negative direction,
negating hypothesis C by indicating more protection from
estrogen after longer hypoestrogenic intervals. It however
deserves mention that since elderly rats or wash-out pe-
riods beyond 2 weeks were used in a low number of stud-
ies, conclusions about these variables should be drawn with
caution (Figure 4). Although no support for hypotheses B
and C was found in the present analysis, researchers havepreviously suggested mechanisms for the detrimental ef-
fects of high age and long periods of hypoestrogenicity.
For example in an article published 2010, Selvamani et al.
put forward that decreasing IGF-1 levels in elderly rats
and further suppression by estrogen treatment is asso-
ciated with a decline in estrogens’ beneficial effects in the
aging brain [11]. Regarding the potential harm of a pro-
longed wash-out period, Suzuki et al. proposed 2007 loss
of anti-inflammatory actions of estrogens as a possible
mechanism [10].
A few other variables were found to significantly
affect the EC-ratio, however since these did not ad-
dress the main hypotheses, we refrain from drawing
conclusions about them, and refer to Table 2 for the in-
terested reader.Strengths and weaknesses
An inherent draw-back with linear regression analysis is
that linear relations are assumed, which evidently is not
always true. This imperfection must be kept in mind
when assessing the results. Another weakness of the
current study is that the 124 group pairs were described
in only 61 articles, which in turn were published by even
fewer research groups. To be perfectly stringent, group
pairs from the same article or the same research group
should not be regarded as independent. However, creat-
ing dummy variables for each article or research group
would have made the analysis totally devoid of statistical
power, and thus impossible to perform.
The analysis presents a composite result of data gath-
ered from 124 group pairs and more than 1900 rats,
handled in a rich variety of experimental conditions. The
main strength of the current meta-analysis is that all fac-
tors that have been suggested to be responsible for the
discrepant results were tested in parallel, thus potently
correcting for confounders.Conclusions
We conclude that the discordant results regarding estro-
gens’ effects in rat models of ischemic stroke are a conse-
quence of differences in estrogen administration modes,
corroborating the earlier systematic analysis from our
laboratory [12]. The clearly protective effects of silastic
capsules and injections contrast the potentially harmful
effects of estrogens delivered via the high-dose slow-
release pellets. Further, the relation between higher pel-
let doses and increased propensity for causing damage
underscores the plausibility that delivered dose is the
culprit, which is reflected in the concept of hormesis.
The meta-analysis could not corroborate the hypotheses
that (B) the age of the experimental animals nor (C) the
length of hypoestrogenicity affected estrogens’ impact
on stroke.
Table 2 Multiple regression analysis
Variable (reference category) Variable categories Regression
coefficient
0.95 Confidence interval for
regression coefficient
p-value
Lower bound Upper bound
Constant/baseline – showing the effect of the reference categories NA 93.4 76.7 110.1
Estrogen administration mode (Slow-release pellets) Injections −31.9 −48.5 −15.2 0.000
Silastic capsules −38.2 −54.9 −21.6 0.000
Per oral −59.3 −129.3 10.7 0.096
Type of middle cerebral artery occlusion procedure (Intraluminal filament) Direct, mechanical 33.2 18.8 47.6 0.000
Embolic −42.0 −90.8 6.7 0.091
Photothrombotic 20.6 −53.1 94.2 0.581
Endothelin injection 2.3 −31.2 35.9 0.891
Laser-doppler flowmetry during surgery (No) [Yes] −15.3 −29.4 −1.2 0.034
Edema correction (No edema correction used) Correcting for edema in infarct −21.8 −54.2 10.6 0.184
Correcting for edema in entire hemisphere −23.1 −39.6 −6.7 0.006
Length of time between initiation of estrogen administration and induction of the ischemic damage Continuous; hours 0.025 0.011 0.040 0.001
Variables excluded in preceding multiple regression analysis (with backward exclusion) due to too low explanatory value: Strain, Sex, Elderly rats, Washout (Length of time between ovariectomy and estrogen




















Daily injected dose [µg/kg body weight]






































Silastic capsule dose [µg/capsule]



















































Slow-release pellet dose [µg/pellet]


















































y=62.8 - 0.002x (NS)
y=63.2 - 0.05x (NS)
Figure 3 By three simple linear regression analyses, it was
found that higher pellet doses significantly increased EC-ratio
(y = 72.8 + 0.05x; p = 0.001), while there was an opposite trend
(not significant) among injection and silastic capsule regimens.
The numbers of group pairs included in the slow-release pellet,
injection and silastic capsule simple regression models were 39, 50
and 31, respectively. Note that the injection graph has been compressed
in the upper dose range to accommodate three group pairs being
administered very high doses.
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Article search and inclusion
To define articles to include in the meta-analysis,
Medline was the 5th of March 2013 searched with the
search line (stroke OR “cerebral ischemia” or “brain in-
farction” or “cerebral infarction” or “brain ischemia” ormcao or “middle cerebral artery occlusion”) AND (es-
trogen OR estradiol OR estrogens) and rat. The articles
retrieved by the search together with the articles in-
cluded in the previously mentioned systematic ana-
lysis, in total 333 papers, were independently assessed
for inclusion by two researchers. A specific study was
included if all the following criteria were met:
A. Article written in English
B. Original research article
C. The experiment was performed in adolescent, adult
or elderly rats
D. The rats were males or ovariectomized and/or
reproductively senescent females
E. Each estrogen treatment group had a
corresponding control group, and no factor except
the estrogen administration per se differed
between the groups
F. No other treatments were administered in parallel to
the estrogen regime
G. One single focal cerebral ischemic lesion was
induced in the animals
H. The estrogens were administered prior to or at the
time of MCAo
I. Infarct sizes were assessed and results presented
Consensus was reached to include 61 studies, of which
45 were included in the previous systematic analysis
[6,8,9,21-62] while 16 were not [11,63-77]. The previous
systematic analysis [12] included not only focal cerebral
ischemia, but also global ischemia, which is really not
a model of ischemic stroke, but rather models the ef-
fects of cardiac arrest on the brain. Also, only studies
using adult rats were included in the current study,
since there are relevant differences in brain patho-
physiology as well as in models for cerebral ischemia
between adult animals and pups. These changes to
make the inclusion criteria more scientifically strin-
gent explain why only 45 of 66 articles from the previ-
ous study were used in the current study. Several
articles included more than one pair of an estrogen-
treated group and a corresponding control group, dif-
fering in for example euthanasia time-point. All these
group pairs were separately included and assessed in-
dependently of each other. In the 61 studies, 124 pairs
of estrogen-treated groups and control groups were
identified.
It was initially the intention to expand the meta-
analysis by setting up parallel models for studies in
mice. However, the search line (stroke OR “cerebral is-
chemia” or “brain infarction” or “cerebral infarction” or
“brain ischemia” or mcao or “middle cerebral artery oc-
clusion”) AND (estrogen OR estradiol OR estrogens) and
(mice or mouse) only identified 22 articles eligible for
0 20 40 60 80 100
[%]







































Transient, up to 60 minutes 24.2%
4.8%
Correcting for edema in entire hemisphere 24.2%
Correcting for edema in infarct 4.0%
Excluded
variables
Figure 4 The frequencies of the different categories in the 124 group pairs are presented as percentages. Please note that the Disease
and Estrogen type variables were omitted from the statistical analysis because too few studies used diseased animals and other estrogens than
17β-estradiol, respectively.
Table 3 Central tendencies and dispersion measures of registered continuous variables




Total number of rats in estrogen treated and control groups 16.0 7.3 15 10-20
Slow-release pellets: estrogen dose/pellet μg 412.6 53.0 180.0 25.0-1000.0
Injections: daily estrogen dose μg/kg body
weight
794.8 3006.2 100.0 11.9-200.0
Silastic capsules: estrogen dose/silastic capsule μg 77.5 124.8 28.0 27.2-28.0
Length of time between initiation of estrogen administration and induction of
the ischemic damage
Hours 221.6 600.5 168 0.5-324
Length of time between ischemia and evaluation of damage Hours 49.6 96.4 24.0 24.0-24.0
Infarct size ratio between estrogen treated and control rats % 72.1 42.3 56.2 43.7-93.9
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planned multiple regression analysis. Further, in only
one single group pair, after isoflurane-preconditioning,
estrogens were found to increase damage from focal
cerebral ischemia. Therefore, it was decided to let rat
studies be the sole focus of this article.
Data extraction
Eighteen pre-defined method and result variables were
extracted from the 61 articles describing the 124
group pairs. Method variables were chosen with the
aim to encompass all methodological aspects that the-
oretically could influence estrogens’ effects on ische-
mia. When extracting the method data, the principle
“If it was not described, it was not performed” was
strictly adhered to. All extracted variables are pre-
sented in Table 1. When possible, categories repre-
sented by less than 5 group pairs were in the analysis
clumped up in an Others category. Further, some other
reductions in number of categories were performed, as
presented under “Variable definitions and cathegoriza-
tions” below.
Processing of data
Variable definitions and categorizations
Sprague Dawley and Wistar were the only strains that were
sufficiently well-used (at least 5 group pairs) to deserve
separate categories. All other registered strains (Lister
hooded rats, Diabetes type 1 rats, Spontaneously hyper-
tensive rats – stroke prone, Spontaneously hypertensive
rats and rats of unknown strain) were put in an Other
strains category.
The category Males in the Sex variable was let to include
both castrated and intact male animals, since castrated
males were used in too few studies (n = 3) to deserve a sep-
arate category.
Too few studies used diseased animals for the Disease
variable to be meaningfully included in the meta-analysis.
The variable was therefore omitted from the statistical
analysis, but is for the sake of transparency presented in
Figure 4.
Elderly rats were defined as being at least 9 months of
age at time of ischemic insult.
The continuous variable Number of rats in estrogen
treated and control groups was calculated by simply
summarizing the number of animals included in the in-
farct size measurements in each group pair.
Slow-release pellets from the company Innovative
Research of America®, various injections and subcuta-
neous silastic capsules defined the three Estrogen ad-
ministration mode categories. The Injection category
consisted mainly of subcutaneous treatments, but a
few group pairs included in this category were treated
with intramuscular, intravenous and intraperitonealinjections. Since the other routes than subcutaneous
were each too small to define separate categories, they
were all included in the injection category. It can be
argued that the pharmacokinetic differences between
the injection regimens are too large to justify grouping
them; however, they do share the important common
characteristic of a high plasma concentration peak
with short duration, which was why it was still deemed
a relevant category [13]. Only one group pair was
treated with 17β-estradiol orally, which was far too
few for meaningful analysis. However, since no other
“superfluous” categories in this variable existed, the
single study was put in a separate Oral treatment
category.
The variable Estrogen type was omitted since only five
groups were treated with other estrogen forms than 17β-
estradiol. Premarin was used in two goups, estradiol val-
erate in one group and estrone in two groups. The vari-
able is nevertheless presented in Figure 4.
The three variables Slow-release pellets: estrogen dose/
pellet, Injections: Daily estrogen dose and Silastic cap-
sules: estrogen dose/silastic capsule presented in Table 1
were not included in the main multiple regression
model, since each of these variables was only relevant
for a limited number of group pairs. These categories
were instead used in subsequent simple linear regression
models.
To deal with the fact that male rats are not ovariecto-
mized, and that no fields in the multiple regression ana-
lysis are allowed to be empty, the variable Washout
(Length of time between ovariectomy and estrogen ad-
ministration) was first separated into two categories, 0–
14 days and >14 days, and then combined with the vari-
able Sex, making Males a third category.
In the variable Type of middle cerebral artery occlusion
procedure, the category Direct, mechanical refers to all
MCAo procedures where the MCA was mechanically oc-
cluded from the outside, for example by clips, cauterization
or ligation. The categories Emboli and Photothrombo-
sis included only 3 and 1 group pairs, but were treated
according to the same principles as the Oral treatment
category above.
Regarding the Occlusion duration variable, only
methods including actions taken to ensure reperfusion
(such as removing the occluding intraluminal filament
or arterial clip) were considered transient.
Regarding the category Laser-Doppler flowmetry dur-
ing surgery, group pairs were put in the [Yes]-category
irrespective of whether or not it was explicitly described
that the laser-Doppler was used to exclude animals.
Edema correction when calculating infarcts sizes can be
performed according to at least two principles. Swanson
et al. [78] described a procedure that focuses on the loss
of viable tissue instead of on the infarct area per se:
Corrected infraction; as part of one hemisphere½  ¼ Total contralateral hemisphere½ − Viable tissue in infarcted hemisphere½ 
Total contralateral hemisphere½ 
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and not outside it, and defined the category Correcting
for edema in infarct. An alternative is to express the in-
farction as a percentage of the ipsilateral hemisphere:
Corrected infarction; as part of one hemisphere½ 
¼ Crude infarct area½ 
Total ipsilateral hemisphere½ 
The assumption here is instead that the edema is
equally distributed in the entire infarcted hemisphere,
and group pairs in which this procedure had been
adopted were registered in the category Correcting for
edema in entire hemisphere.
The outcome variable Infarct size ratio between estro-
gen treated and control rats (in the text referred to as
“EC-ratio”) was calculated by simply dividing the mean
infarct volume in the estrogen treated group by the
mean infarct volume in the control group, and then
multiplying by 100 to yield a percentage. Hence, a per-
centage above 100% means that the estrogen group on
average suffered from larger (nominally; whether signifi-
cant or not) infarctions than the control group, while
numbers below 100% indicates the opposite. For ex-
ample, a group pair in which estrogen treatment halved
the infarct size would obtain an EC-ratio of 50%.
Statistical analyses
To identify which methodological factors significantly af-
fected the EC-ratio, multiple linear regression analysis
was used. As abovementioned, this analysis was the most
important improvement from our previous systematic
analysis [12]. While the different methodological vari-
ables were analyzed separately in the previous article,
the current meta-analysis combined them all in a large
multiple regression model. In this main model, EC-ratio
was the outcome variable, Number of rats in estrogen
treated and control groups attributed each group pair a
weight in the analysis, and all other extracted variables
(except the aforementioned excluded ones, and the ad-
ministration mode-specific dose variables) were consid-
ered independent factors. All category variables were
dummy-converted before analysis. The main multiple re-
gression analysis consisted of two steps. First, a multiple
regression model with Backward exclusion of variables
(p-value set to 0.10 for exclusion) was performed to
eliminate independent factors that did not significantly
contribute to the model (the variables excluded due totoo low explanatory value are listed in the bottom of
Table 2). Subsequently, the final multiple regression
model, with an Enter procedure, including the signifi-
cantly affecting variables from the previous model (to-
gether with lacking dummy variables so that all
categories within a certain variable were included), was
run. The results from the final multiple regression ana-
lysis is presented in Figure 2 and Table 2.
Also, group pairs in which slow-release pellets, injec-
tions and silastic capsules had been used, respectively,
were separately analyzed for association between dosage
and EC-ratio. Even if three further large multiple
models, as the main model described above, would the-
oretically have been preferable to control for con-
founders, the number of groups pairs pertaining to any
of the three administration mode categories was too low
(in the range of 30–50) to sustain an adequate statistical
power. Instead, the relation between dosage and EC-
ratio was analyzed with simple linear regression models.
The results from these are presented in Figure 3. Three
group pairs received silastic capsules containing crystal-
lized 17β-estradiol, and were excluded from this analysis
due to difficulty in translating to dissolved concentra-
tions. In two of these three group pairs, estrogens were
protective, while no difference was seen in the third
group pair.
All statistical calculations were performed in SPSS
(Version 20, IBM Corporation, Armonk, NY, USA). P-
values <0.05 were considered statistically significant.Protocol violations
As mentioned earlier, the variables Disease and Estrogen
type was omitted from the analysis, since too few group
pairs included diseased animals or were administered
other estrogens than 17β-estradiol, respectively.
One study [40] lacked information about the weight-
variable Number of rats in estrogen treated and control
groups, and the group pair was arbitrarily given the aver-
age weight of all other group pairs.
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